Literature DB >> 2731977

Comparison of the reactivities and immunogenicities of procholeragenoid and the B subunit of cholera toxin in Thai volunteers.

S Migasena1, P Pitisuttitham, P Suntharasamai, B Prayurahong, W Supanaranond, V Desakorn, R E Black.   

Abstract

Procholeragenoid, a stable high-molecular-weight aggregate of cholera toxin derived by heat treatment, was evaluated for reactivity and immunogenicity in adult Thai volunteers. Since procholeragenoid is known to retain some residual activity of cholera toxin, increasing amounts were ingested until diarrhea occurred; 250 micrograms induced diarrhea, but 100 micrograms did not. Procholeragenoid and cholera toxin B subunit, both in 100-micrograms amounts, were then compared for systemic and intestinal antitoxin responses. When three peroral doses were given, these immunogens gave comparable responses. The secretory immunoglobulin A antitoxin responses to three doses of 100 micrograms of B subunit did not differ significantly from responses found in previous studies of Thai adults given 1 or 5 mg of B subunit, but serum antitoxin responses were less after 1 or 2 doses of 100 micrograms than after doses of 1 or 5 mg. Serum antitoxin levels were similar after 3 doses of B subunit. Procholeragenoid in the maximum safe dose of 100 micrograms does not offer any immunologic advantage over B subunit, although it may be less expensive and easier to produce. However, these studies suggest that higher amounts of B subunit are more immunogenic and may be preferable, if found to be sufficiently cost effective, when added to oral killed whole Vibrio cholerae vaccines.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2731977      PMCID: PMC313824          DOI: 10.1128/iai.57.7.1942-1945.1989

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  18 in total

1.  Intestinal antibody responses after immunisation with cholera B subunit.

Authors:  A M Svennerholm; D A Sack; J Holmgren; P K Bardhan
Journal:  Lancet       Date:  1982-02-06       Impact factor: 79.321

2.  Protection against experimental cholera by oral or parenteral immunization.

Authors:  J W Peterson
Journal:  Infect Immun       Date:  1979-11       Impact factor: 3.441

3.  Immunogenicity of two formulations of oral cholera vaccine comprised of killed whole vibrios and the B subunit of cholera toxin.

Authors:  S Migasena; V Desakorn; P Suntharasamai; P Pitisuttitham; B Prayurahong; W Supanaranond; R E Black
Journal:  Infect Immun       Date:  1989-01       Impact factor: 3.441

4.  Antigenicity of cholera toxoid in humans.

Authors:  R Germanier; E Fürer; S Varallyay; T M Inderbitzin
Journal:  J Infect Dis       Date:  1977-04       Impact factor: 5.226

5.  Protection against colibacillosis in neonatal piglets by immunization of dams with procholeragenoid.

Authors:  E Fürer; S J Cryz; F Dorner; J Nicolet; M Wanner; R Germanier
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

6.  Procholeragenoid: an aggregated intermediate in the formation of choleragenoid.

Authors:  R A Finkelstein; K Fujita; J J LoSpalluto
Journal:  J Immunol       Date:  1971-10       Impact factor: 5.422

7.  Preparation of a purified antigenic cholera toxoid.

Authors:  R Germanier; E Fürer; S Varallyay; T M Inderbitzin
Journal:  Infect Immun       Date:  1976-06       Impact factor: 3.441

8.  Receptor-specific large-scale purification of cholera toxin on silica beads derivatized with lysoGM1 ganglioside.

Authors:  J L Tayot; J Holmgren; L Svennerholm; M Lindblad; M Tardy
Journal:  Eur J Biochem       Date:  1981-01

9.  Oral immunization of dogs with purified cholera toxin, crude cholera toxin, or B subunit: evidence for synergistic protection by antitoxic and antibacterial mechanisms.

Authors:  N F Pierce; W C Cray; J B Sacci
Journal:  Infect Immun       Date:  1982-08       Impact factor: 3.441

10.  Microtiter enzyme-linked immunosorbent assay for immunoglobulin G cholera antitoxin in humans: method and correlation with rabbit skin vascular permeability factor technique.

Authors:  C R Young; M M Levine; J P Craig; R Robins-Browne
Journal:  Infect Immun       Date:  1980-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.